Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem(R) by UNICEF to Support Vaccination Programs in the Developing World

LEIDEN, The Netherlands, May 6, 2010 - Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ:
CRXL; Swiss Exchange: CRX) today announced the award from UNICEF of an
additional $110 million to supply its paediatric vaccine Quinvaxem(R) to the
developing world. Paediatric vaccination plays an important role in
contributing to achieving the Millennium Development Goals set by the United
Nations, in particular the target of reducing under-five mortality rate by
two-thirds between 1990 and 2015. "We are proud to be able to deliver
significant amount of additional vaccine orders at short notice," said Ronald
Brus, Crucell's Chief Executive Officer. "The capacity and reliability of
Crucell's manufacturing and logistical systems allows us to deliver high
quality and safe vaccines to protect young children from life threatening
diseases in the world's developing countries. As a responsible and reliable
partner, we thus contribute to the success of the Global Alliance for
Vaccines and Immunisation (GAVI Alliance) in accelerating access to these
vaccines across the globe."

From 2006-2009 as part of the Extended Program for Immunization, over 130
million doses of Quinvaxem(R) have been delivered to more than 50 countries.
Crucell has been increasing its production capacity over the last few years
in order to meet the growing demand for paediatric vaccines from the
developing world.

Quinvaxem(R) is the only fully liquid pentavalent DTwP-HepB-Hib vaccine
that is free from the preservative thiomersal. It is an optimal solution for
protection against five potentially deadly childhood diseases: diphtheria,
tetanus, pertussis, Haemoplilus influenza type b infection and hepatitis B.
Quinvaxem(R) is ready for use without further preparation steps by healthcare
workers in the field, which offers major healthcare advantages for these
countries with a challenging infrastructure and hygiene problems.

This latest order brings the overall value of tenders awarded to Crucell
for the period of 2010-2012 to $410 million. This is in addition to the $500
million obtained over the tender period 2007-2009. They bring the total value
of contracts awarded since the launch of Quinvaxem(R) at the end of 2006 to
$910 million. During the first tender round in 2006, Crucell was initially
awarded $230 million (December 2006) and received additional incremental
awards of $130 million and $140 million in May and September 2008,
respectively.

Forward-looking statements

This press release contains forward-looking statements that involve
inherent risks and uncertainties. We have identified certain important
factors that may cause actual results to differ materially from those
contained in such forward-looking statements. For information relating to
these factors please refer to our Form 20-F, as filed with the US Securities
and Exchange Commission on April 7, 2010, in the section entitled 'Risk
Factors'. The Company prepares its financial statements under International
Financial Reporting Standards (IFRS).

About Crucell

Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a
global biopharmaceutical company focused on research development, production
and marketing of vaccines, proteins and antibodies that prevent and/or treat
infectious diseases. In 2009 alone, Crucell distributed more than 115 million
vaccine doses in more than 100 countries around the world, with the fast
majority of doses (97%) going to developing countries. Crucell is one of the
major suppliers of vaccines to UNICEF and the developing world. Crucell was
the first manufacturer to launch a fully-liquid pentavalent vaccine called
Quinvaxem(R). Quinvaxem(R) protects against five important childhood diseases
and over 130 million doses have been sold since its launch in 2006 in more
than 50 GAVI countries. Through Quinvaxem(R) and its innovation, Crucell has
become a major partner in protecting children in developing countries.
Crucell's core portfolio also includes a vaccine against hepatitis B and a
virosome-adjuvanted vaccine against influenza. Crucell also markets travel
vaccines, such as an oral anti-typhoid vaccine, an oral cholera vaccine and
the only aluminum-free hepatitis A vaccine on the market. The Company has a
broad development pipeline, with several product candidates based on its
unique PER.C6(R) production technology. The Company licenses its PER.C6(R)
technology and other technologies to the biopharmaceutical industry.
Important partners and licensees include Johnson & Johnson, DSM Biologics,
sanofi-aventis, Novartis, Wyeth, GSK, CSL and Merck & Co. Crucell is
headquartered in Leiden, the Netherlands, with subsidiaries in Argentina,
China, Italy, Korea, Spain, Sweden, Switzerland, UK and the USA. The Company
employs over 1200 people. For more information, please visit
www.crucell.com.

For further information please contact Crucell: Oya Yavuz, Vice President Corporate Communications & Investor Relations, Tel. +31(0)71-519-7064, ir at crucell.com